Adimmune Corporation announced the marketing authorization of the Company's quadrivalent influenza vaccine is granted by China's National Medical Products Administration. Upon receiving the marketing authorization from China's National Medical Products Administration, the Company will initiate the marketing of quadrivalent influenza vaccine for adults.